Julie D. Horan

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Karen Kelly, Nasser K. Altorki, Wilfried Eberhardt et al. · Journal of Clinical Oncology · 2015 · 485 citations · Full text

Medicine, Oncology, Pharmacology +14

A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.

Karen Kelly, Nasser K. Altorki, Wilfried Eberhardt et al. · Journal of Clinical Oncology · 2014 · 44 citations

Medicine, Oncology, Pharmacology +15

Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study

Regina I. Jakacki, Margaret A. Foley, Julie D. Horan et al. · Journal of Neuro-Oncology · 2016 · 30 citations

Medicine, Oncology, Pediatrics +8

Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying <i>EGFR-</i>sensitizing mutations from the RADIANT trial.

Frances A. Shepherd, Nasser K. Altorki, Wilfried Eberhardt et al. · Journal of Clinical Oncology · 2014 · 21 citations

Medicine, Oncology, Pharmacology +17

Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors

Alejandro D. Ricart, Jordan Berlin, Kyriakos P. Papadopoulos et al. · Clinical Cancer Research · 2008 · 17 citations · Full text

Pharmacy, Oncology, Pharmacology +17